Changes in IGF-I, urinary free cortisol and adipokines during dronabinol therapy in anorexia nervosa: Results from a randomised, controlled trial

Andries, Alin; Frystyk, Jan; Flyvbjerg, Allan; Støving, René Klinkby

doi:10.1016/j.ghir.2015.07.006

Cited by 24 publications

(21 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… Placebo n.a. Primary outcomes Tourette Syndrome Symptoms List, Shapiro Tourette Syndrome Severity Scale, Yale Global Tic Severity Scale, Tourette, other assessment instruments, and adverse events Swiss Federal Office of Public Health (FOPH), grant agreement 14.001443/204.0001/-1257 RCTs were judged at “high risk of bias” (GRADE) Small sample size in addition to a large number of scores and subscores tested Lack of statistical power Inclusion of unmedicated and medicated patients 1 Low Hay et al [ 28 ] Andries et al [ 5 , 6 ] SR n * = 1 RCT n ** = 24 Anorexia nervosa (DSM-IV) for at least 5 years Dronabinol (2 × 2.5 mg/d) (duration 4 wks.) Placebo n.a.…”

Section: Resultsmentioning

confidence: 99%

“…Anorexia nervosa (ICD 10 F50.0) One systematic review [ 28 ] of 1 RCT [ 5 – 7 ] was found. This study tested the effects of dronabinol (2 × 2.5 mg/day; 4 weeks) as add-on to standard psychotherapy and eating management in a sample of women with severe (> 5 years) anorexia nervosa (DSM-IV-TR) ( n = 25).…”

Section: Resultsmentioning

confidence: 99%

“…For all other mental disorders, only single studies are available regarding the efficacy of THC-based medicine in these conditions. The reported therapeutic benefits in primary outcomes are: weight gain in patients with therapy-resistant anorexia nervosa (1 RCT) [ 5 – 7 ], improvement of nightmares and well-being in patients with posttraumatic stress disorder (1 RCT) [ 36 ]. In patients with attention-deficit hyperactivity disorder improvement in cognition and activity level did not reach statistical significance (1 RCT) [ 18 ].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review

Hoch

Niemann

Keller

et al. 2019

Eur Arch Psychiatry Clin Neurosci

View full text Add to dashboard Cite

We conducted a review of systematic reviews (SRs) and randomized-controlled trials (RCTs) to analyze efficacy and safety of cannabis-based medication in patients with mental disorders. Five data bases were systematically searched (2006—August 2018); 4 SRs (of 11 RCTs) and 14 RCTs (1629 participants) were included. Diagnoses were: dementia, cannabis and opioid dependence, psychoses/schizophrenia, general social anxiety, posttraumatic stress disorder, anorexia nervosa, attention-deficit hyperactivity disorder, and Tourette`s disorder. Outcome variables were too heterogeneous to conduct a meta-analysis. A narrative synthesis method was applied. The study quality was assessed using the risk-of-bias tool and SIGN-checklists. THC- and CBD-based medicines, given as adjunct to pharmaco- and psychotherapy, were associated with improvements of several symptoms of mental disorders, but not with remission. Side effects occurred, but severe adverse effects were mentioned in single cases only. In order to provide reliable treatment recommendations, more and larger RCTs with follow-up assessments, consistent outcome measures and active comparisons are needed.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review

Hoch

Niemann

Keller

et al. 2019

Eur Arch Psychiatry Clin Neurosci

View full text Add to dashboard Cite

show abstract

“…Activation of the HPA axis through high plasmatic levels of cortisol and corticotrophin-releasing factor (CRF) have been observed in AN patients [9], and decreased after treatment [10]. Recently, Scharner et al reported activation of CRF in distinct brain nuclei, in female ABA mice [11].…”

Section: Hpa Axis Activationmentioning

confidence: 99%

New therapeutic approaches to target gut-brain axis dysfunction during anorexia nervosa

Achamrah

Déchelotte

Coëffier

2019

Clinical Nutrition Experimental

View full text Add to dashboard Cite

Dysregulation of gut-brain axis seems to play a key role in anorexia nervosa (AN) pathophysiology. Central alterations of hypothalamic epituitaryeadrenal axis, neurotransmission, food intake regulation, and peripheral alterations of gut barrier, gut microbiota, immune system, have been reported in AN. Potential beneficial effects of physical activity on gut-brain axis have been observed during refeeding in AN. As nutritional support, psychotherapy, anxiolytics, antidepressants, programmed physical activity needs to be considered as a novel therapeutic tool in AN management. In the future, combined strategies of gut-brain modulations should be assessed in AN, including other promising candidates, probiotics, glutamine and omega-3 fatty acids.

show abstract

“…CBD and THCV had significant positive effect compared to placebo on reduction of fasting plasma glucose, pancreatic β‐cell function, adiponectin and apolipoprotein A, but dronabinol had no clinically meaningful metabolic effect. The sample size in these studies was relatively small: 13 to 130 subjects . The therapeutic effects of cannabinoids, specifically cannabidiol (CBD), on epilepsy, mainly in young adults and children, were investigated in three trials .…”

mentioning

confidence: 99%

Medical cannabis: aligning use to evidence‐based medicine approach

Schleider

Abuhasira

Novack

2018

Brit J Clinical Pharma

View full text Add to dashboard Cite

During the past decade we have been witnessing a rise in medical cannabis use, yet the evidence for the safety and efficacy of the various cannabinoid compounds is scarce. The State of Israel has always been at the forefront of clinical and translational research in support of Evidence Based Medicine. With respect to cannabis Israel has created a medical and regulatory environment that enables clinical studies with cannabis which may lead to improved Evidence Based use of these compounds. This opinion paper discusses selected studies into the safety and effects of cannabis derived products.

show abstract

Changes in IGF-I, urinary free cortisol and adipokines during dronabinol therapy in anorexia nervosa: Results from a randomised, controlled trial

Cited by 24 publications

References 39 publications

How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review

How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review

New therapeutic approaches to target gut-brain axis dysfunction during anorexia nervosa

Medical cannabis: aligning use to evidence‐based medicine approach

Contact Info

Product

Resources

About